Clinical trials
Amyloidosis trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Recruiting | 7 |
| Terminated | 5 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alnylam Pharmaceuticals | 8 |
| GlaxoSmithKline | 6 |
| Ionis Pharmaceuticals, Inc. | 5 |
| Eidos Therapeutics, a BridgeBio company | 3 |
| Janssen Research & Development, LLC | 3 |
| Pfizer | 3 |
| Alexion Pharmaceuticals, Inc. | 2 |
| Intellia Therapeutics | 2 |
| Prothena Biosciences Ltd. | 2 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyloidosis | 40 |
| Amyloid Neuropathies, Familial | 12 |
| Cardiomyopathies | 10 |
| Alzheimer Disease | 6 |
| Immunoglobulin Light-chain Amyloidosis | 6 |
| Amyloidosis, Familial | 5 |
| Polyneuropathies | 5 |
| Amyloid Neuropathies | 2 |
| Heart Diseases | 2 |
| Recurrence | 2 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.